About

Matthew Fenn has nearly 20 years of experience in the healthcare sector. He joined Copley at the start of 2023, coming from Jabil, the world’s largest manufacturing solutions provider for the healthcare industry. With a background in medical devices, pharmaceutical delivery systems and consumer health products that includes a long spell at 3M Health Care, Mr Fenn has specialist technical and sales support knowledge ideal for supporting customers across a wide range of pharmaceutical testing applications.

Contributions

PULMONARY

BETTER IN VIVO PREDICTION FROM OINDP TESTING: A GOAL WORTH PURSUING?

Matthew Fenn and Clair Brooks, consider the motivation for adopting more clinically representative test set-ups in orally inhaled and nasal drug product development and, more specifically, for the demonstration of bioequivalence, as well as the practicalities of doing so and the tools available to support such efforts.